Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
241
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome

Ayaka Sakakia Department of Hematology/Oncology, Wakayama Medical University, Wakayama, JapanView further author information
,
Hiroki Hosoia Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan;b Department of Internal Medicine, Kainan Municipal Medical Center, Wakayama, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8682-7476View further author information
ORCID Icon,
Hideki Kosakoa Department of Hematology/Oncology, Wakayama Medical University, Wakayama, JapanView further author information
,
Yoshiaki Furuyab Department of Internal Medicine, Kainan Municipal Medical Center, Wakayama, JapanView further author information
,
Ryuta Iwamotoc Department of Human Pathology, Wakayama Medical University, Wakayama, JapanView further author information
,
Takayuki Hiroib Department of Internal Medicine, Kainan Municipal Medical Center, Wakayama, JapanView further author information
,
Shogo Murataa Department of Hematology/Oncology, Wakayama Medical University, Wakayama, JapanView further author information
,
Toshiki Mushinoa Department of Hematology/Oncology, Wakayama Medical University, Wakayama, JapanView further author information
,
Shin-Ichi Muratac Department of Human Pathology, Wakayama Medical University, Wakayama, JapanView further author information
&
Takashi Sonokia Department of Hematology/Oncology, Wakayama Medical University, Wakayama, JapanView further author information
 show all
Pages 2499-2502 | Received 18 Mar 2022, Accepted 03 May 2022, Published online: 13 May 2022

References

  • Masaki Y, Arita K, Sakai T, et al. Castleman disease and TAFRO syndrome. Ann Hematol. 2022;101(3):485–490.
  • Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–1364.
  • Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94(9):975–983.
  • Kawabata H, Fujimoto S, Sakai T, et al. Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114(2):179–188.
  • Fujimoto S, Kawabata H, Sakai T, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021;113(1):73–80.
  • Kuwana M, Okazaki Y, Ikeda Y. Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia. PLoS One. 2014;9(1):e86943.
  • Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.
  • Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103(6):686–692.
  • Meguri Y, Asada N, Nakasako Y, et al. A case report of TAFRO syndrome successfully treated by immunosuppressive therapies with plasma exchange. Ann Hematol. 2019;98(2):537–539.
  • Zwaginga JJ, van der Holt B, Te Boekhorst PA, Dutch HOVON 64 study group, et al. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica. 2015;100(3):e90–e92.
  • Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009;83(4):365–372.
  • Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–1753.
  • Noda-Narita S, Sumida K, Sekine A, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7(1):162–168.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.